Abstract Details
8/21/2022 | 3:15 PM - 4:15 PM | Governor General II
Overview of Screening, Diagnosis, and Interprofessional Care for Infants & Children with cCMV
Congenital cytomegalovirus is one of the leading causes of nongenetic congenital hearing loss and is also associated with delayed onset of hearing loss in infants and children. The goal of early hearing detection and intervention (EHDI) is to maximize linguistic and communicative competence and literacy development for children who are hard of hearing or deaf. Achieving this result is dependent upon the early detection of, and intervention for, deaf and hard of hearing infants. This is achieved through integrated, interdisciplinary state and national systems of universal newborn hearing screening (UNHS), evaluation, and family-centered intervention. Increasingly, screening for cCMV is being incorporated into UNHS protocols which leads to earlier identification of infants with cCMV that are otherwise asymptomatic. This session will provide an overview of the medical and audiologic evaluation of infants and children identified with cCMV who are symptomatic and asymptomatic, with or without hearing loss. Recommended audiologic monitoring for those with cCMV that do not present with hearing loss will be discussed, as well as recommended follow-up and intervention for those who do have decreased hearing sensitivity. The screening process will be discussed and there will be a focus on providing a background for understanding audiologic test results and recommendations for treatment or monitoring, depending on individual infant/child needs. There will also be an overview of the hearing loss issues and considerations unique to infants/children with cCMV. The session will highlight the importance of interprofessional practice, with various providers who support the network of care, highlight parental issues related to newborn hearing screening and cCMV, diagnosis, and emphasize the importance of building collaborative partnerships between families, early intervention programs, pediatric audiology providers, otolaryngologists, and the medical home.
- Participants will be able to describe the appropriate follow-up services required for infants/children with cCMV and diverse hearing screening outcomes and diagnostic findings.
- Participants will be able to discuss the types of hearing loss observed in infants and children with cCMV and the medical/diagnostic assessments and treatments appropriate for each.
- Participants will be able to discuss interprofessional collaborations that can enhance outcomes for cCMV children identified with hearing loss.
Presentation:
This presentation has not yet been uploaded.
Handouts:
No handouts have been uploaded.
Albert Park (Co-Presenter), albert.park@hsc.utah.edu;
Dr. Park is the chief for Pediatric Otolaryngology at the University of Utah. He is the principal investigator for an NIH funded multi-institutional clinical trial to determine whether the antiviral drug, valganciclovir can improve hearing outcomes for children with cytomegalovirus (CMV), a very common and understudied cause of childhood hearing loss.He also established a CMV working group comprising of pediatric genetics, infectious disease, otolaryngology, audiology, neurology, department of health and ARUP laboratories to streamline clinical and research initiatives in this field.
|
ASHA DISCLOSURE: Financial - No relevant financial relationship exists. Nonfinancial - No relevant nonfinancial relationship exists. |
|
AAA DISCLOSURE: Financial - Receives support for NIH U01 PI CMV multi-institutional study ASPO grant- CMV related Office of Naval Research – Drug Delivery I3 Grant- CMV . |
Angela Shoup (Primary Presenter), angela.shoup@utdallas.edu;
Angela Shoup, Ph.D. is Professor of Otolaryngology and Chief of the Division of Communicative and Vestibular Disorders at the University of Texas Southwestern Medical Center. Dr. Shoup is affiliated with UT Southwestern clinics in Dallas, Ft. Worth and Frisco, Parkland Hospital and Childrens Health facilities. Dr. Shoup has published articles and textbook chapters on audiologic procedures and implantable hearing aids. She has been an invited speaker at national and international meetings. She served as President of the Texas Academy of Audiology, Chair of the Ethical Practices Committee for the American Academy of Audiology, Chair of the American Academy of Audiology Foundation Board of Trustees, and as a member of the Board of Directors for the American Academy of Audiology. She is currently serving as President-Elect of the American Academy of Audiology and as Vice-Chair of the National Academies of Practice Audiology Academy.
|
ASHA DISCLOSURE: Financial - No relevant financial relationship exists. Nonfinancial - Has a Professional (Serve on scientific advisory committee) relationship for Volunteer membership on advisory committee or review panels. |
|
AAA DISCLOSURE: Financial - Receives support from National CMV Foundation for Serve on scientific advisory committee. |